Takeda Pharmaceutical Company
Tracked across 6 events · 64 articles · First seen Feb 19, 2026 · Last active Jul 02, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Business
Impact: Takeda Pharmaceutical Company is partnering with Insilico Medicine to integrate AI into its drug discovery process, aiming to accelerate the identification of novel drug candidates and transition to an AI-native discovery model. This collaboration grants Takeda exclusive worldwide rights to develop and commercialize therapeutics from this partnership.
Jul 02, 2026 · 8 articles
Business
Impact: Takeda Pharmaceutical Company terminated its collaboration agreement with Denali Therapeutics for DNL593 due to strategic considerations, not related to efficacy or safety data.
Apr 03, 2026 · 7 articles
Business
Impact: Takeda Pharmaceutical's stock declined, showing a negative performance.
May 21, 2026 · 31 articles
Tech
Impact: Takeda Pharmaceutical Company Limited is a funding partner for the project, supporting the research into Alzheimer s disease biomarkers.
Feb 19, 2026 · 6 articles
Tech
Impact: Takeda Pharmaceutical Company is a sponsor of World Hemophilia Day 2026, supporting the World Federation of Hemophilia's efforts.
Apr 17, 2026 · 6 articles
Business
Impact: Takeda Pharmaceutical Company is licensed to develop and commercialize rusfertide, another peptide therapeutic discovered by AnBogen Therapeutics.
Jun 16, 2026 · 6 articles
100
Insilico Medicine entered collaboration agreement Takeda Pharmaceutical CompanyInsilico Medicine, Takeda...
95
Insilico Medicine will receive payments Takeda Pharmaceutical CompanyInsilico Medicine, Takeda...
90
Takeda Pharmaceutical Company granted exclusive rights Insilico MedicineInsilico Medicine, Takeda...
ERGEN INTELLIGENCE
Track Takeda Pharmaceutical Company live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard